Table 2 Anti-influenza virus activities and cellular toxicities of selected peptides.

From: A “building block” approach to the new influenza A virus entry inhibitors with reduced cellular toxicities

Name

IC50 ± SD (μM) a

CC50 ± SD (μM) b

H3N2 c

H1N1 d

H1N1 e

H1N1 f

H3 (690) g

H3 (699) g

B g

HaCaT

C18-Jp

4.65 ± 1.24

11.55 ± 0.21

1.44 ± 0.11

3.24 ± 1.65

11.28 ± 4.86

4.29 ± 1.89

1.94 ± 1.51

40.59 ± 3.01

C20-Hp

4.62 ± 1.36

16.00 ± 3.72

4.17 ± 0.04

18.29 ± 4.10

5.43 ± 1.29

2.45 ± 0.37

4.53 ± 3.68

21.78 ± 0.25

Ribavirin

24.93 ± 1.10

17.11 ± 3.60

12.85 ± 0.08

NT h

8.47 ± 3.01

4.92 ± 1.45

6.71 ± 0.93

NT

C18-Hp-Jp

3.15 ± 0.93

5.25 ± 0.54

0.75 ± 0.18

NT

6.03 ± 2.96

NT

2.19 ± 0.29

37.45 ± 1.19

C20-Hp-Jp

2.97 ± 0.55

4.80 ± 0.66

0.71 ± 0.37

5.41 ± 1.39

2.47 ± 2.59

1.24 ± 0.08

1.31 ± 0.16*

33.72 ± 1.58

C18-Jp-Hp

1.63 ± 0.65

2.19 ± 0.43

0.61 ± 0.04

NT

3.55 ± 0.92

2.28 ± 0.50

3.60 ± 1.01

50.17 ± 2.94

C20-Jp-Hp

1.32 ± 0.31

1.71 ± 0.09

0.53 ± 0.25

1.59 ± 0.52

2.38 ± 1.66

1.95 ± 0.59

0.66 ± 0.60

41.48 ± 0.71

C20-ALLSA-Hp

10.51 ± 0.58

4.27 ± 3.42

1.69 ± 1.38

NT

NT

NT

NT

NT

C20 -Hp-ALLSA

8.90 ± 1.89

11.92 ± 6.19

3.80 ± 2.88

NT

NT

NT

NT

NT

  1. aThe data was obtained by CPE assay;
  2. bThe toxicity was evaluated with MTT assay;
  3. cA/Aichi/2/68;
  4. dA/FM/1/47 mouse adapted strain;
  5. eA/Puerto Rico/8/34;
  6. fA/Puerto Rico/8/34 with NA-H274Y mutation. Zanamivir was used as negative control, it IC50 toward A/Puerto Rico/8/34 with NA-H274Y mutation is 16.88 ± 2.43 μM and 0.31 ± 0.06 μM against A/Puerto Rico/8/34 (H1N1);
  7. g690 (H3), 699 (H3), and influenza B virus were clinical isolates;
  8. hNT: not tested.
Back to article page